NEW YORK (GenomeWeb News) – Rosetta Genomics today said in its earnings report for the fourth quarter of 2007 that it is “solidly on target” to launch three diagnostic microRNA tests in the coming year, but as it currently has no products on the market it posted no revenues for 2007.
 
In addition, the company’s net loss nearly tripled as it spent more on increased R&D and selling and general expenses rose.  
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.